Zevra Therapeutics (ZVRA) Convertible Debt (2014 - 2020)

Zevra Therapeutics has reported Convertible Debt for 7 years, with the latest figure at $67.7 million in Q4 2020.

• For the quarter ending Q4 2020, Convertible Debt fell 12.52% year-over-year to $67.7 million; the trailing twelve-month figure through Dec 2020 stood at $67.7 million (down 12.52% YoY), and the FY2020 full-year result was $67.7 million, down 12.52% from the prior year.
• Convertible Debt for Q4 2020 stood at $67.7 million, down from $77.3 million in the prior quarter.
• The five-year high for Convertible Debt was $92.3 million in Q3 2017, with the low at $67.7 million in Q4 2020.
• Historically, Convertible Debt has averaged $84.5 million across 5 years, with a median of $89.4 million in 2017.
• Annual changes were most pronounced in 2016 — Convertible Debt soared 1130.03% — and 2019, when it decreased 19.06%.
• Zevra Therapeutics' Convertible Debt stood at $91.2 million in 2016, then fell by 1.94% to $89.4 million in 2017, then decreased by 12.63% to $78.1 million in 2018, then slipped by 0.98% to $77.3 million in 2019, then fell by 12.52% to $67.7 million in 2020.
• The last three Convertible Debt figures came in at $67.7 million (Q4 2020), $77.3 million (Q4 2019), and $70.6 million (Q3 2019), per Business Quant data.